Butorphanol Tartrate NDC 72162-2099

NDC codes

FDA NDC Directory

Product NDC (as listed)72162-2099Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72162-2099Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72162-2099-2	72162209902	1 BOTTLE, SPRAY in 1 CONTAINER (72162-2099-2) / 2.5 mL in 1 BOTTLE, SPRAYMarketed from Sep 19, 2023

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Butorphanol Tartrate
Generic name (nonproprietary): butorphanol tartrate
Active ingredients: Butorphanol tartrate — 10 mg/mL
Dosage form: Spray
Route: Nasal
Labeler: Bryant Ranch Prepack
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 075499
Marketing start: Dec 4, 2002
Listing expires: Dec 31, 2027
DEA schedule: CIV
Other FDA classes: Competitive Opioid Antagonists (Mechanism)Partial Opioid Agonists (Mechanism)
Identifiers: Product ID 72162-2099_2ed74d4d-331d-4663-9dfd-1e87ea1a3a78SPL ID 2ed74d4d-331d-4663-9dfd-1e87ea1a3a78SPL set ID 412499ce-db93-4943-ae1a-564c27b1fb16RxCUI 886634UNII 2L7I72RUHN
Pharmacologic class: Opioid Agonist/Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Nasal products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472162209902 followed by a unit qualifier and the quantity

Package 72162-2099-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 20, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS AND USAGE Butorphanol tartrate nasal spray is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use : Because of the risks of addiction, abuse, and misuse, with opioids, which can occur at any dosage or duration [see WARNINGS ] reserve butorphanol tartrate nasal spray for use in patients for whom alternative treatment options (e.g., non-opioid analgesics): Have not been tolerated, or are not expected to be tolerated, Have not provided adequate analgesia, or are not expected to provide adequate analgesia Butorphanol tartrate nasal spray should not be used for an extended period of t…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 075499

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 075499
Product	Strength	Form · route	Labeler	Product NDC
Butorphanol Tartrate	Butorphanol tartrate 10 mg/mL	SprayNasal	Apotex Corp.	60505-0813